{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:54:19Z","timestamp":1792688059167,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-03852-x","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T14:03:27Z","timestamp":1715954607000},"page":"313-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["An observational study on the safety of teprotumumab based on FAERS database"],"prefix":"10.1007","volume":"85","author":[{"given":"Xing-Long","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Bo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"3852_CR1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/cen.14296","volume":"93","author":"YH Chin","year":"2020","unstructured":"Y.H. Chin, C.H. Ng, M.H. Lee, J.W.H. Koh, J. Kiew et al. Prevalence of thyroid eye disease in Graves\u2019 disease: A meta-analysis and systematic review. Clin. Endocrinol. 93, 363\u2013374 (2020)","journal-title":"Clin. Endocrinol."},{"key":"3852_CR2","doi-asserted-by":"crossref","unstructured":"H.B. Burch, P. Perros, T. Bednarczuk, D.S. Cooper, P.J. Dolman et al. Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association. Eur. Thyroid J. 11, e220189 (2022)","DOI":"10.1530\/ETJ-22-0189"},{"key":"3852_CR3","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"L. Bartalena, G.J. Kahaly, L. Baldeschi, C.M. Dayan, A. Eckstein et al. The 2021 European Group on Graves\u2019 Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur. J. Endocrinol. 185, G43\u2013G67 (2021)","journal-title":"Eur. J. Endocrinol."},{"key":"3852_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/IOP.0000000000001959","volume":"37","author":"SB Diniz","year":"2021","unstructured":"S.B. Diniz, L.M. Cohen, K.A. Roelofs, D.B. Rootman, Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population. Ophthalmic Plast. Reconstr. Surg. 37, 583\u2013591 (2021)","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"3852_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/IOP.0000000000002267","volume":"39","author":"TC Ho","year":"2023","unstructured":"T.C. Ho, R.N. Maamari, A.L. Kossler, C.M. Sears, S.K. Freitag et al. Outcomes of patients with thyroid eye disease partially treated with teprotumumab. Ophthalmic Plast. Reconstr. Surg. 39, 150\u2013155 (2023)","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"3852_CR6","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","volume":"9","author":"GJ Kahaly","year":"2021","unstructured":"G.J. Kahaly, R.S. Douglas, R.J. Holt, S. Sile, T.J. Smith, Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 9, 360\u2013372 (2021)","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3852_CR7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/ICU.0000000000000997","volume":"34","author":"PS Subramanian","year":"2023","unstructured":"P.S. Subramanian, R.I. Cho, A. Kahana, Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease. Curr. Opin. Ophthalmol. 34, 487\u2013492 (2023)","journal-title":"Curr. Opin. Ophthalmol."},{"key":"3852_CR8","doi-asserted-by":"publisher","first-page":"101348","DOI":"10.1016\/j.ajoc.2022.101348","volume":"26","author":"KB Vinson","year":"2022","unstructured":"K.B. Vinson, M. Kirzhner, Effects of teprotumumab on patients with long-standing, active thyroid eye disease. Am. J. Ophthalmol. Case Rep. 26, 101348 (2022)","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"3852_CR9","doi-asserted-by":"publisher","first-page":"e654","DOI":"10.1210\/clinem\/dgad213","volume":"108","author":"MN Stan","year":"2023","unstructured":"M.N. Stan, C.C. Krieger, The adverse effects profile of teprotumumab. J Clin Endocrinol Metab 108, e654\u2013e662 (2023)","journal-title":"J Clin Endocrinol Metab"},{"key":"3852_CR10","doi-asserted-by":"crossref","unstructured":"J.A. Keen, T. Correa, C. Pham, A.D. Claussen, M.R. Hansen et al. Frequency and patterns of hearing dysfunction in patients treated with teprotumumab. Ophthalmology 131, 30\u201336 (2023)","DOI":"10.1016\/j.ophtha.2023.08.001"},{"key":"3852_CR11","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/ohn.174","volume":"168","author":"E Kay-Rivest","year":"2023","unstructured":"E. Kay-Rivest, I. Belinsky, A. Kozlova, E. Byrd, S.O. McMenomey et al. Prospective assessment of otologic adverse events due to teprotumumab: preliminary results. Otolaryngol. Head Neck Surg. 168, 1164\u20131169 (2023)","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"3852_CR12","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1210\/clinem\/dgac627","volume":"108","author":"L Amarikwa","year":"2023","unstructured":"L. Amarikwa, A. Mohamed, S.H. Kim, A.L. Kossler, C. Dosiou, Teprotumumab-related hyperglycemia. J. Clin. Endocrinol. Metab. 108, 858\u2013864 (2023)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3852_CR13","doi-asserted-by":"crossref","unstructured":"R.T. Patel, D.J. Grider, N. Ramey, Novel teprotumumab treatment of severe thyroid dermopathy; ototoxicity as an adverse side effect. Dermatol. Online J. 29, 5 (2023)","DOI":"10.5070\/D329160211"},{"key":"3852_CR14","unstructured":"Z.P. Li, W.B. Zou, J. Yuan, Y.X. Zhong, Z.W. Fu, Gender differences in adverse events related to osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system. Expert Opin. Drug Saf. (2023)"},{"key":"3852_CR15","doi-asserted-by":"crossref","unstructured":"C. Carter, M. Marks, A.W. Bundeff, T. Adewodu, L. Alderman, A case of rapidly declining glycemic control and diabetic ketoacidosis in a newly diagnosed diabetes patient after starting teprotumumab for thyroid eye disease. Endocrine 83, 65\u201368 (2024)","DOI":"10.1007\/s12020-023-03531-3"},{"key":"3852_CR16","first-page":"134","volume":"122","author":"MD Yee","year":"2023","unstructured":"M.D. Yee, J. McCarthy, B. Quinn, A. Surani, Teprotumumab-induced encephalopathy: a rare side effect of a novel therapeutic. WMJ 122, 134\u2013137 (2023)","journal-title":"WMJ"},{"key":"3852_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1089\/thy.2023.0466","volume":"34","author":"RS Douglas","year":"2024","unstructured":"R.S. Douglas, E. Parunakian, J. Tolentino, E. Malkhasyan, J. Geng et al. A Prospective Study Examining Audiometry Outcomes Following Teprotumumab Treatment for Thyroid Eye Disease. Thyroid 34, 134\u2013137 (2024)","journal-title":"Thyroid"},{"key":"3852_CR18","doi-asserted-by":"crossref","unstructured":"A.K. Terrarosa, L.N. DeMaria, V.S. North, M.D. Garcia, E.T. Kim et al. Menstrual irregularities and amenorrhea in thyroid eye disease patients treated with teprotumumab. Ophthalmic Plast. Reconstr. Surg. (2024)","DOI":"10.1097\/IOP.0000000000002569"},{"key":"3852_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Y. Jiang, L. Zhou, Y. Shen, Q. Zhou, Y. Ji et al. Safety assessment of Rrexpiprazole: real-world adverse event analysis from the FAERS database. J. Affect. Disord. 346, 223\u2013229 (2024)","journal-title":"J. Affect. Disord."},{"key":"3852_CR20","doi-asserted-by":"publisher","first-page":"109283","DOI":"10.1016\/j.yebeh.2023.109283","volume":"145","author":"P Liu","year":"2023","unstructured":"P. Liu, Y. Zhang, X. Xu, M. Zhou, Y. Fei et al. Mining and analysis of adverse drug reactions associated with perampanel based on FAERS database. Epilepsy Behav. 145, 109283 (2023)","journal-title":"Epilepsy Behav."},{"key":"3852_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","volume":"240","author":"CM Sears","year":"2022","unstructured":"C.M. Sears, A.D. Azad, L. Amarikwa, B.H. Pham, C.J. Men et al. Hearing dysfunction after treatment with teprotumumab for thyroid eye disease. Am. J. Ophthalmol. 240, 1\u201313 (2022)","journal-title":"Am. J. Ophthalmol."},{"key":"3852_CR22","doi-asserted-by":"publisher","first-page":"2473974X2210970","DOI":"10.1177\/2473974X221097097","volume":"6","author":"W Najjar","year":"2022","unstructured":"W. Najjar, J. Yu, Audiologic demonstration of ototoxicity from teprotumumab treatment in a patient with thyroid eye disease. OTO Open 6, 2473974X221097097 (2022)","journal-title":"OTO Open"},{"key":"3852_CR23","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1177\/00034894211042740","volume":"131","author":"J Highland","year":"2022","unstructured":"J. Highland, S. Gordon, D. Reddy, N. Patel, Ototoxicity and teprotumumab. Ann. Otol. Rhinol. Laryngol. 131, 910\u2013913 (2022)","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"3852_CR24","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s40618-022-01791-w","volume":"45","author":"L Bartalena","year":"2022","unstructured":"L. Bartalena, M. Marino, C. Marcocci, M.L. Tanda, Teprotumumab for Graves\u2019 orbitopathy and ototoxicity: moving problems from eyes to ears? J. Endocrinol. Investig. 45, 1455\u20131457 (2022)","journal-title":"J. Endocrinol. Investig."},{"key":"3852_CR25","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1097\/MAO.0000000000003428","volume":"43","author":"AS Ding","year":"2022","unstructured":"A.S. Ding, N.R. Mahoney, A.A. Campbell, F.X. Creighton, Sensorineural hearing loss after teprotumumab therapy for thyroid eye disease: a case report. Otol. Neurotol. 43, e148\u2013e152 (2022)","journal-title":"Otol. Neurotol."},{"key":"3852_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/IOP.0000000000001995","volume":"38","author":"I Belinsky","year":"2022","unstructured":"I. Belinsky, F.X. Creighton Jr., N. Mahoney, C.K. Petris, A.B. Callahan et al. Teprotumumab and hearing loss: case series and proposal for audiologic monitoring. Ophthalmic Plast. Reconstr. Surg. 38, 73\u201378 (2022)","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"3852_CR27","doi-asserted-by":"publisher","first-page":"E638","DOI":"10.1200\/JCO.2010.34.5116","volume":"29","author":"M Daher","year":"2011","unstructured":"M. Daher, M.E. Lacouture, D. Rathkopf, R.G. Maki, M.L. Keohan et al. Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab. J. Clin. Oncol. 29, E638\u2013E640 (2011)","journal-title":"J. Clin. Oncol."},{"key":"3852_CR28","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1038\/emboj.2008.141","volume":"27","author":"H Stachelscheid","year":"2008","unstructured":"H. Stachelscheid, H. Ibrahim, L. Koch, A. Schmitz, M. Tscharntke et al. Epidermal insulin\/IGF-1 signalling control interfollicular morphogenesis and proliferative potential through Rac activation. Embo J. 27, 2091\u20132101 (2008)","journal-title":"Embo J."},{"key":"3852_CR29","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1128\/MCB.26.7.2675-2687.2006","volume":"26","author":"M Sadagurski","year":"2006","unstructured":"M. Sadagurski, S. Yakar, G. Weingarten, M. Holzenberger, C.J. Rhodes et al. Insulin-like growth factor 1 receptor signaling regulates skin development and inhibits skin keratinocyte differentiation. Mol. Cell Biol. 26, 2675\u20132687 (2006)","journal-title":"Mol. Cell Biol."},{"key":"3852_CR30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s004030050469","volume":"291","author":"A Tavakkol","year":"1999","unstructured":"A. Tavakkol, J. Varani, J.T. Elder, C.C. Zouboulis, Maintenance of human skin in organ culture: role for insulin-like growth factor-1 receptor and epidermal growth factor receptor. Arch. Dermatol. Res. 291, 643\u2013651 (1999)","journal-title":"Arch. Dermatol. Res."},{"key":"3852_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/0-387-26274-1_4","volume":"567","author":"CA Bondy","year":"2005","unstructured":"C.A. Bondy, J. Zhou, Growth hormone, insulin-like growth factors and the female reproductive system. Adv. Exp. Med. Biol. 567, 91\u2013115 (2005)","journal-title":"Adv. Exp. Med. Biol."},{"key":"3852_CR32","unstructured":"T.P. Information, (2023) Available at: https:\/\/www.hzn-docs.com\/TEPEZZA-Prescribing-Information.pdf."},{"key":"3852_CR33","doi-asserted-by":"crossref","unstructured":"T. Subramani, V. Rathnavelu, N.B. Alitheen, The possible potential therapeutic targets for drug induced gingival overgrowth. Mediat. Inflamm 2013, 639468 (2013)","DOI":"10.1155\/2013\/639468"},{"key":"3852_CR34","doi-asserted-by":"crossref","unstructured":"Y. Noguchi, T. Tachi, H. Teramachi, Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform. 22, 1\u201334 (2021)","DOI":"10.1093\/bib\/bbab347"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03852-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-03852-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03852-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T05:02:14Z","timestamp":1720846934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-03852-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["3852"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-03852-x","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]},"assertion":[{"value":"15 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}